Subsequently, the same group demonstrated that a decrease of 18F-FDG-avidity in tumour and spleen as well as the general 18F-FDG-avid tumour burden 3 months after initiation of anti-PD-1-treatment were associated with improved clinical outcome [55]. Here, PDCD1 is linked to neoplasm.